Biopharma Leaders Unite to Prioritize Safety in Covid-19 Vaccine Development

Strategic Insights -

Nine top pharmaceutical companies, including AstraZeneca, BioNTech, and Pfizer, have signed a joint pledge to prioritize the safety of vaccinated individuals in the development of a Covid-19 vaccine. This commitment is outlined in a four-point pledge that emphasizes adherence to high scientific and ethical standards during clinical trials and the application for approvals after the Phase 3 clinical study process as per FDA regulations. US President Donald Trump has also made optimistic statements about the rapid development of a coronavirus vaccine, aiming for production in "record time" and a potential delivery as early as October.

Key Takeaways:

  • Nine pharmaceutical companies, including AstraZeneca, BioNTech, and Pfizer, have signed a joint pledge to prioritize the safety of vaccinated individuals in Covid-19 vaccine development.
  • The pledge outlines four key commitments, including adherence to high scientific and ethical standards during clinical trials and applications for approvals after the Phase 3 clinical study process as per FDA regulations.
  • US President Donald Trump has expressed confidence in the rapid development of a coronavirus vaccine, aiming for production in "record time" and a potential delivery as early as October.
  • The US currently ranks first globally in coronavirus cases and deaths, with almost 6.3 million confirmed cases nationwide and about 190,000 deaths.
  • The CEOs of the nine pharmaceutical companies signed the pledge, including Merck, Moderna, Novavax, and Sanofi.

Statistics:

  • 6.3 million: The number of confirmed Covid-19 cases in the US as of the latest reported data.
  • 190,000: The number of reported Covid-19 deaths in the US as of the latest reported data.
  • 9: The number of pharmaceutical companies that have signed the joint pledge to prioritize safety in Covid-19 vaccine development.
  • 4: The number of key commitments outlined in the pledge, including adherence to high scientific and ethical standards and applications for approvals after the Phase 3 clinical study process.

Sources:

  • KUNA : Biopharma leaders unite to stand with science - Science & Technology - 08/09/2020 (https://www.kuna.net.kw/ArticleDetails.aspx?id=2920686&Language=en)
  • CategoryPage.Aspx (CategoryPage.Aspx?Id=111&Language=En)